Science & ResearchAug 30, 2026
Autotaxin Inhibition Ameliorates HFpEF Phenotype By Reducing LPA-Mediated Systemic Inflammation And Cardiac Remodeling
Background: HFpEF accounts for roughly half of heart failure admissions and lacks disease-modifying therapy.
Background: HFpEF accounts for roughly half of heart failure admissions and lacks disease-modifying therapy. Autotaxin (ENPP2) generates lysophosphatidic acid (LPA), a profibrotic and pro-inflammatory bioactive lipid. Whether circulating lysophospholipid metabolism is altered in…
Sign in to learn & save →
The frontier is open to all. Sign in to learn this from first principles and save it to your knowledge base.